Department of Ophthalmology, Reference Center for Rare Diseases, La Pitié-Salpêtrière Hospital, Paris-Sorbonne University, Paris, 75013, France.
Department of Ophthalmology, Fondation Rothschild, Université de Paris, Paris, 75019, France.
Immunotherapy. 2021 Dec;13(18):1465-1481. doi: 10.2217/imt-2021-0032. Epub 2021 Oct 28.
We report the long-term outcome of uveitis associated with cancer immunotherapy (CIT). This retrospective review included serial patients with CIT-associated uveitis treated using various regimen. Eight patients treated with rituximab (anti-CD20), nivolumab (anti-PD-1), ipilimumab (anti-CTLA-4), vemurafenib and dabrafenib (anti-BRAF), trametinib (anti-MEK) and ibritunib showed uveitis with hypopion (one patient), macular edema (five patients) and choroiditis (two patients). Various regimens of corticosteroid therapy showed a favorable ophthalmological outcome, whether the CIT was continuing or suspended. Local corticosteroid injections in combination with CIT could be suggested as a first-line treatment. This could help to preserve the quality of life without threatening the vital prognosis.
我们报告了癌症免疫治疗（CIT）相关葡萄膜炎的长期结果。这项回顾性研究纳入了使用各种方案治疗的 CIT 相关葡萄膜炎的连续患者。8 名接受利妥昔单抗（抗 CD20）、纳武单抗（抗 PD-1）、伊匹单抗（抗 CTLA-4）、vemurafenib 和 dabrafenib（抗 BRAF）、trametinib（抗 MEK）和 ibritunib 治疗的患者出现了低眼压性葡萄膜炎（1 例）、黄斑水肿（5 例）和脉络膜炎（2 例）。无论 CIT 是否继续或暂停，皮质类固醇治疗的各种方案均显示出良好的眼科结局。局部皮质类固醇注射联合 CIT 可作为一线治疗。这有助于在不威胁生命预后的情况下提高生活质量。
